Case Study of the WeekAbout: News/Events
Molecular Diagnostics Company, RedPath, Appoints Jack Davis to Board of Directors
Pittsburgh, PA, August 20, 2009 – RedPath Integrated Pathology, Inc., a molecular diagnostics company dedicated to the effective diagnosis and treatment of cancer, today announced that it has appointed Jack Davis to RedPath’s Board of Directors.
Mr. Davis brings more than forty years experience in Life Science executive management to RedPath. He has helped entrepreneurs and investors bring their breakthrough technologies to the market for the benefit of cancer patients and their health care providers.
Mr. Davis’ professional career includes co-founder, President/COO and later CEO, of Dianon Systems, Inc., which he built from a venture capital backed start-up to a $200 million leading provider of cutting edge Clinical and Anatomic Pathology based solutions for clinicians. Previously, he was the Division Vice President and General Manager of Abbot Diagnostic’s $100 million worldwide Diagnostic Products business unit. Mr. Davis has also served on the Board of Directors of over twelve companies; taken two companies public as CEO and sold three other companies as either Chairman or Director.
Currently, Mr. Davis serves on the Board of Directors of Claros Diagnostics Inc., a leading developer of point of care diagnostic test systems; Laboratory Partners, Inc., a large regional full service clinical and anatomic pathology laboratory company; and Collages.Net, Inc., a leading web based source for products and services serving the professional photography industry. In addition, Mr. Davis is non-executive Chairman of the Board of Asterand, Inc., a publically traded, leading provider of human tissue and tissue services used in drug discovery and development by the Pharmaceutical and Biotech industry.
“I feel privileged and excited to be joining the Board of Directors of RedPath Integrated Pathology,” commented Davis. “RedPath is a leader in the development and commercialization of genomics based cancer diagnostic tools which enable physicians to deliver the best medicine possible to their cancer patients. I look forward to helping the company meet the needs of their physician clients, patients, employees and shareholders in their mission to facilitate superior disease diagnosis.”
Mark D. Myslinski, RedPath’s President and Chief Executive Officer, commented that he is thrilled to have Jack Davis on the Board of Directors and looks forward to working with Mr. Davis who brings additional management, laboratory and diagnostic acumen to RedPath Integrated Pathology. “Jack Davis and I share a vision to improve the lives of people with cancer by applying novel diagnostic tools that solve clinical patient management dilemmas.”
Additionally, Brian Murphy, Partner of NewSpring Capital and Chairman of the Board for RedPath observed, "The fact that RedPath was able to recruit someone of Mr. Davis' caliber to the Board is testimony that the company has made significant progress since Mark Myslinski joined the company as CEO." Mr. Murphy added, "The addition of Mr. Davis to the Board provides the company with much needed strategic capabilities as it looks to grow to the next level."
About RedPath Integrated Pathology Inc.
RedPath Integrated Pathology, Inc. is a genomics-based molecular diagnostics company that provides complex cancer diagnostic testing for pathologists, oncologists and clinicians. RedPath’s patented molecular-based analysis, PathFinderTG®, integrates with routine pathology review of fixed slides, cytology and fluid specimens to render an earlier and more definitive diagnosis, improving patient outcomes and reducing healthcare costs. For more information about RedPath, please visit www.redpathip.com